8R-Lisuride Is a Potent Stereospecific Histamine H1-Receptor Partial Agonist
Authors:
- R. A. BakkerRBR. A. Bakker
- D. M. WeinerDWD. M. Weiner
- T. ter LaakTLT. ter Laak
- T. BeumingTBT. Beuming
- O. P. ZuiderveldOZO. P. Zuiderveld
- M. EdelbroekMEM. Edelbroek
- U. HacksellUHU. Hacksell
- H. TimmermanHTH. Timmerman
- M. R. BrannMBM. R. Brann
- R. LeursRLR. Leurs
- 1 March 2004
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 65 (3) , 538-549
Abstract
The human histamine H1 receptor (H1R) is an important, well characterized target for the development of antagonists to treat allergic conditions. Many neuropsychiatric drugs are known to potently antagonize the H1R, thereby producing some of their side effects. In contrast, the tolerability and potential therapeutic utility of H1R agonism is currently unclear. We have used a cell-based functional assay to evaluate known therapeutics and reference drugs for H1R agonist activity. Our initial functional screen identified three ergot-based compounds possessing heretofore-unknown H1R agonist activity. 8R-lisuride demonstrated potent agonist activity in various assays including receptor selection and amplification technology, inositol phosphate accumulation, and activation of nuclear factor-κB with pEC50 values of 8.1, 7.9, and 7.9, respectively, and with varying degrees of efficacy. Based on these assays, 8R-lisuride is the most potent stereospecific partial agonist for the human H1R yet reported. Investigation of the residues involved in histamine and lisuride binding, using H1R mutants and molecular modeling, have revealed that although these ligands are structurally different, the lisuride-binding pocket in the H1R closely corresponds to the histamine-binding pocket. The discovery of a potent stereospecific partial H1R agonist provides a valuable tool to further characterize this important therapeutic target in vitro.Keywords
This publication has 61 references indexed in Scilit:
- Histamine H1-Receptor Activation of Nuclear Factor-κB: Roles for Gβγ- and Gαq/11-Subunits in Constitutive and Agonist-Mediated SignalingMolecular Pharmacology, 2001
- Constitutive activity of the histamine H1 receptor reveals inverse agonism of histamine H1 receptor antagonistsEuropean Journal of Pharmacology, 2000
- Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s DiseaseEuropean Neurology, 2000
- Agonist activity of LSD and lisuride at cloned 5HT 2A and 5HT 2C receptorsPsychopharmacology, 1998
- Interaction of Tryptamine and Ergoline Compounds with Threonine 196 in the Ligand Binding Site of the 5-Hydroxytryptamine6 ReceptorMolecular Pharmacology, 1997
- A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic MoleculesJournal of the American Chemical Society, 1995
- Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortexGeneral Pharmacology: The Vascular System, 1986
- Actions of betahistine at histamine receptors in the brainEuropean Journal of Pharmacology, 1985
- Direct action of d-lysergic acid diethylamide on dispersed mucosal cells from guinea pig stomachBiochemical Pharmacology, 1982
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976